MONDAY, SEPTEMBER 23 | 12:30 – 3:00 pm
SC1: Gene Edited Cell-Based Therapies: Opportunities and Challenges - Detailed Agenda
Khalid Shah, MS, PhD, Director, Center for Stem Cell Therapies and Imaging, Harvard Medical School; Vice Chair of Research, Brigham and Women’s Hospital
H. Trent Spencer, PhD, Associate Professor of Pediatrics; Director, Gene and Cell Therapy Program in the Aflac Cancer and Blood Disorders Center, Emory University School of Medicine; President and Co-Founder, Expression Therapeutics LLC
Additional Instructors to be Announced
Engineered cell-based therapies are yielding promising clinical benefits for treating many diseases, especially cancer. This course will cover some of the important topics such as sources of therapeutic cells (stem cells, T cells, NK cells and cancer
cells), novel engineered viral vectors and their engineering capabilities, the role of CRISPR gene editing and clinical translation and safety aspects of engineered cell therapies. The instructors will give short talks followed by open discussion
with attendees, where they can elaborate on their experiences and expertise.
MONDAY, SEPTEMBER 23 | 3:30 – 6:00 pm
SC2: Understanding and Modulating Tumor Microenvironment for Immunotherapy - Detailed Agenda
RJ Tesi, MD, CEO, CMO, INmune Bio
Mark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London
This interactive short course tackles our emerging understanding of the role of the tumor microenvironment (TME) in tumor immunotherapy. The TME can have a marked immunosuppressive effect leading to suboptimal responses of tumors to immunotherapies. Strategies
to change the immunosuppressive nature of the TME to one that supports immune responses and enhances the impact of tumor immunotherapy will be discussed.
*Separate registration required.